TPL2 mediates autoimmune inflammation through activation of the TAK1 axis of IL-17 signaling
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Development of autoimmune diseases, such as multiple sclerosis and experimental autoimmune encephalomyelitis (EAE), involves the inflammatory action of Th1 and Th17 cells, but the underlying signaling mechanism is incompletely understood. We show that the kinase TPL2 is a crucial mediator of EAE and is required for the pathological action of Th17 cells. TPL2 serves as a master kinase mediating the activation of multiple downstream pathways stimulated by the Th17 signature cytokine IL-17. TPL2 acts by linking the IL-17 receptor signal to the activation of TAK1, which involves a dynamic mechanism of TPL2–TAK1 interaction and TPL2-mediated phosphorylation and catalytic activation of TAK1. These results suggest that TPL2 mediates TAK1 axis of IL-17 signaling, thereby promoting autoimmune neuroinflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475 · cited 2×
“IL-17 is the prototypical member of a family of related cytokines and has been linked to the pathogenesis of both MS and other autoimmune diseases (Gaffen, 2009; Iwakura et al., 2011; Zepp et al., 2011; Song and Qian, 2013).”
BackgroundFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Qian, Y., Liu, C., Hartupee, J., Altuntas, C. Z., Gulen, M. F., Jane-wit, D., Xiao, J., Lu, Y., Giltiay, N., Liu, J., et al. (2007) · Nature Immunology · doi:10.1038/ni1439 · Cited by 614
Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor
Chang, S. H., Park, H., & Dong, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600256200 · Cited by 356 · cited 1×
“The cytoplasmic region of IL-17R contains a signaling domain, the SEF/IL-17R domain, which interacts with the adaptor protein ACT1 (also called CIKS) in response to IL-17 stimulation (Novatchkova et al., 2003; Chang et al., 2006; Qian et al., 2007).”
BackgroundSchwandner, R., Yamaguchi, K., & Cao, Z. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1233 · Cited by 349 · cited 5×
“Analogous to the TLRs, the IL-17R signals through the recruitment of an adaptor molecule, ACT1, and utilizes TRAF members, particularly TRAF6.”
BackgroundInfluentialKang, Z., Altuntas, C. Z., Gulen, M. F., Liu, C., Giltiay, N., Qin, H., Liu, L., Qian, W., Ransohoff, R. M., Bergmann, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.004 · Cited by 297 · cited 4×
“Genetic evidence suggests that IL-17 signaling in neuroectoderm-derived CNSresident cells, particularly astrocytes, plays a crucial role in mediating EAE pathogenesis (Kang et al., 2010).”
BackgroundResultInfluentialThe STIR-domain superfamily in signal transduction, development and immunity
Novatchkova, M., Leibbrandt, A., Werzowa, J., Neubüser, A., & Eisenhaber, F. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00067-7 · Cited by 255
Sun, D., Novotny, M., Bulek, K., Liu, C., Li, X., & Hamilton, T. (2011) · Nature Immunology · doi:10.1038/ni.2081 · Cited by 232
Act1, a U-box E3 Ubiquitin Ligase for IL-17 Signaling
Liu, C., Qian, W., Qian, Y., Giltiay, N. V., Lu, Y., Swaidani, S., Misra, S., Deng, L., Chen, Z. J., & Li, X. (2009) · Science Signaling · doi:10.1126/scisignal.2000382 · Cited by 224 · cited 2×
“Conversely, ACT1 and TRAF6 are largely dispensable for IL-17–stimulated activation of the MAP kinase ERK (Qian et al., 2007; Liu et al., 2009).”
BackgroundBulek, K., Liu, C., Swaidani, S., Wang, L., Page, R. C., Gulen, M. F., Herjan, T., Abbadi, A., Qian, W., Sun, D., et al. (2011) · Nature Immunology · doi:10.1038/ni.2080 · Cited by 192
Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation
Xiao, Y., Jin, J., Chang, M., Chang, J.-H., Hu, H., Zhou, X., Brittain, G. C., Stansberg, C., Torkildsen, Ø., Wang, X., et al. (2013) · Nature Medicine · doi:10.1038/nm.3111 · Cited by 184
Self-citation
Cited by
IL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785
NF-κB and the Transcriptional Control of Inflammation
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.07.007 · Cited by 498
The role of IL-17 in CNS diseases
Waisman, A., Hauptmann, J., & Regen, T. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1402-7 · Cited by 340
Interleukin-17 in chronic inflammatory neurological diseases
Milovanovic, J., Arsenijevic, A., Stojanovic, B., Kanjevac, T., Arsenijevic, D., Radosavljevic, G., Milovanovic, M., & Arsenijevic, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00947 · Cited by 250
Control of autoimmune CNS inflammation by astrocytes
Rothhammer, V., & Quintana, F. J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0515-3 · Cited by 214
Metadata
- Authors
- Xiao, Y., Jin, J., Chang, M., Nakaya, M., Hu, H., Zou, Q., Zhou, X., Brittain, G. C., Cheng, X., & Sun, S.-C.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-06-30
- Volume
- 211
- Issue
- 8
- Pages
- 1689-1702
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2169477525
- Cited by
- 71
- References
- 12
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.